EXICURE, INC.
Chicago, United States · Biotechnology, Health Care, Other
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Key facts
- Headquarters
- Chicago, United States
- Employees
- 8
- Industries
- Biotechnology, Health Care, Other
- Status
- Public (XCUR)
- Website
- exicure.com
- Company page
Recent activity at EXICURE, INC.
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On May 28, 2026, Exicure, Inc. received a notification from Nasdaq indicating non-compliance with Listing Rule 5250(c)(1) due to a delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This delay was linked to changes in the Company's financial reporting personnel. The Company subsequently filed the 10-Q on May 29, 2026, and believes it has regained compliance with Nasdaq regulations. The event highlights the Company's efforts to address its reporting practices and maintain its listing status on Nasdaq.
- : Exicure Appoints Yoontae Han as Director and Audit Committee Member
- : SEC 8-K (5.02): On April 8, 2026, Exicure, Inc. appointed Yoontae Han as a director of the Company and to the Audit Committee, with an annual retainer of $20,000. Additionally, on April 9, 2026, the Company appointed Young Seung Ko as Chief Operating Officer, bringing over 20 years of experience in enterprise software and corporate governance. This change signifies a strategic enhancement in leadership, particularly with Mr. Ko's extensive background in financial oversight and regulatory compliance, which could bolster the Company’s operations and governance structure. Both appointments are effective immediately and highlight the Company’s focus on strengthening its management team.
- : SEC 8-K (5.02): On April 8, 2026, Exicure, Inc. appointed Yoontae Han as a director of the Company and a member of the Audit Committee. This appointment is effective immediately and will remain until a successor is elected or he is removed. Additionally, Dongho Lee was appointed as Chair of the Audit Committee. Mr. Han will receive an annual retainer of $20,000 for his services. This appointment reflects the company's ongoing commitment to strong corporate governance and oversight in its financial practices.
- : SEC 8-K (8.01):
- : SEC 8-K (5.02): On March 25, 2026, Sangjin Yeo resigned from the Board of Directors and the Audit Committee of Exicure, Inc. This resignation is effective as of March 27, 2026, and it did not arise from any disagreements concerning the Company's operations or policies. This change in board composition may have implications for the governance and decision-making processes at Exicure as they transition to new leadership dynamics.
- : SEC 8-K (2.02): On March 25, 2026, Exicure, Inc. reported its financial and operational results for the year ended December 31, 2025. The announcement includes detailed outcomes from the previous fiscal year, which reflect the company's performance and operational highlights. This event is significant for investors as it provides insights into the company's financial health and future outlook. The press release is furnished as Exhibit 99.1 to the current report, but it is noted that the information is not deemed 'filed' under applicable securities laws.
- : Exicure, Inc. Appoints New CEO and Interim CFO
- : SEC 8-K (5.02):
EXICURE, INC. funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2022 | Venture | $5.4M |
| Aug 2018 | Venture | $22.0M |
| Jul 2017 | Pre-Seed | $6K |
Leadership
- Matthias Schroff, CEO
- Jay Venkatesan, Director
- Helen Kim, Director
- David Walt, Director
- David Giljohann, Executive Officer, Director
- C. Thaxton, Director
- Chad Mirkin, Director
- Mark Tompkins, Director
- Ian Jacobs, Executive Officer, Director
- Josh Miller, Chief Accounting Officer
- Elina Protasova, Senior Accountant
- Yoontae Han, Director
Verified email and direct lines for EXICURE, INC.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
EXICURE, INC. in the news
- Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - Yahoo Finance (Jun 01, 2026)
- Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. - BioSpace (Jan 23, 2025)
- Exicure Agrees to $5.625 Million Settlement in Securities Class Action - Claim Depot (Nov 08, 2024)
- Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - Yahoo Finance (Apr 22, 2026)
- Chicago CEO steps down after just two months on the job - The Business Journals (Feb 04, 2022)
- Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements - Business Wire (Dec 14, 2022)
- Exicure (XCUR) Stock Price, News & Analysis - MarketBeat (Oct 22, 2020)
- Exicure, Inc. (XCUR) Company Information - Simply Wall Street (Sep 18, 2022)
Companies similar to EXICURE, INC.
- Ajax Therapeutics, Inc. · Biotechnology, Health Care, Other, Therapeutics
- Strata Oncology · Biotechnology, Health Care, Other, Therapeutics
- Vor Bio · Biotechnology, Health Care, Other, Therapeutics
- CERo Therapeutics Holdings · Biotechnology, Health Care, Other, Therapeutics
- Gallant · Biotechnology, Health Care, Other, Therapeutics
About EXICURE, INC.: questions and answers
What does EXICURE, INC. do?
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Where is EXICURE, INC. headquartered?
EXICURE, INC. is headquartered in Chicago, United States.
How many employees does EXICURE, INC. have?
EXICURE, INC. has about 8 employees.
Has EXICURE, INC. raised funding?
Yes. Fundz has recorded 3 funding events for EXICURE, INC.. The most recent, $5.4M, was in Sep 2022.
Who leads EXICURE, INC.?
Matthias Schroff is a CEO at EXICURE, INC..
What is the latest news on EXICURE, INC.?
On Jun 30, 2026, SEC 8-K (5.02):
Is EXICURE, INC. a public company?
Yes. EXICURE, INC. is publicly traded under the ticker XCUR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy